Amaran Biotech, a leading Taiwanese CDMO (Contract Development & Manufacturing Organization) offering comprehensive pharmaceutical development and manufacturing solutions, is making its debut at BioJapan 2024 in Yokohama from October 9 to 11. The company is participating as part of Taiwan’s Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) delegation. Amaran Biotech will showcase its services at the Taiwan Pavilion (Booth No. B-56), including its vaccine adjuvant AB-801 (QS-21), drug substance manufacturing, drug product manufacturing, and stability study and analytical science services. Visitors are invited to meet with Amaran Biotech's representatives at the event.
In the field of immunology and vaccine development, adjuvants are vital components that enhance the immune response elicited by vaccines. One such adjuvant, QS-21, a natural product extracted from the bark of the soap bark tree (Quillaja saponaria), is an attractive candidate for use in vaccines.
Equipment that complies with good manufacturing practice (GMP) is essential for producing pharmaceutical products that are pure, safe and effective. The design, function, qualification and control of such equipment must meet high standards in the manufacture of these products.
BIO Asia–Taiwan 2024, an international gathering jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO); will be held from July 24th to 28th at the Taipei Nangang Exhibition Center. Amaran Biotech’s booth(#M413) will be located at CDMO (Contract Development and Manufacturing Organization) zone, please visit us and meet with our representatives.
It is well known that human intervention increases the risk of finished product sterility failure during the aseptic filling process. For traditional aseptic filling lines using RABS, human intervention is often required, such as adjusting conveyor belts, turntables, vibrating bowls, star wheels through gloves.
When it comes to the production of sterile products, EU GMP Annex 1 is the highest standard that pharmaceutical manufacturers must adhere to. To provide a Class A environment and ensure sterility, barrier technology (either isolators or RABS) is the best solution to address critical factors such as quality of air, material and ingredient transfer, decontamination, etc. mentioned in Annex 1.